- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6453
Project Team
- Project lead
- Jeremy.Powell@nice.org.uk
Email enquiries
If you have any queries please email TATeam2@nice.org.uk
Stakeholders
- Companies sponsors
- SpringWorks Therapeutics (Nirogacestat)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Beacon
- Black Health Agency for Equality
- Cancer 52
- Cancer Black Care
- Desmoid Aid UK
- Desmoid Fibromatosis Patients & Caregivers UK
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- Tenovus Cancer Care
- Sarcoma UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of Cancer Physicians
- Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
- British Association of Surgical Oncology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Sarcoma Group
- Cancer Research UK
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- UK Clinical Pharmacy Association
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Amarox (imatinib mesilate)
- Bayer (sorafenib tosilate)
- Cipla (imatinib mesilate)
- Dr Reddy’s Laboratories (imatinib mesilate)
- Grindeks Kalceks (imatinib mesilate)
- Novartis Pharmaceuticals (pazopanib hydrochloride, imatinib mesilate)
- Orion Pharma (imatinib mesilate)
- Sandoz (sorafenib tosilate, imatinib mesilate)
- Thornton & Ross (sorafenib tosilate)
- Zentiva (sorafenib tosilate)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Gut
- Genomics England
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 July 2025 | Invitation to participate |
| 16 April 2025 - 19 May 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID6453 |
| 16 April 2025 | In progress. Scoping commenced. |
| 12 December 2024 | Referral |
| 30 May 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 30 May 2024 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual